https://www.massachusettshealthcarejournal.com/article/905494291-the-nssc-releases-statement-following-stephenson-king-jr-s-death-a-triple-systemic-failure Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 The NSSC Releases Statement Following Stephenson King Jr.'s Death: A Triple Systemic Failure https://www.massachusettshealthcarejournal.com/article/905639051-what-drives-wuxi-apptec-s-25-year-compliance-record-and-why-does-it-matter-for-global-partnerships Massachusetts Healthcare Journal en PressRelease 2026-04-14T09:10:29+00:00 What Drives WuXi AppTec’s 25-Year Compliance Record, and Why Does It Matter for Global Partnerships? https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24832182-a-global-company-operating-in-a-1920x1080.jpeg https://www.massachusettshealthcarejournal.com/article/905673841-inspira-technologies-appoints-yoav-rozanovich-as-chief-business-officer-to-drive-immediate-revenue-growth-and-quantum-expansion Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:01:00+00:00 Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://www.massachusettshealthcarejournal.com/article/905669423-community-routes-access-to-mental-health-care-provides-continued-funding-for-mental-health-services-at-free-charitable-clinics Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905669681-amneal-launches-first-two-respiratory-metered-dose-inhalation-products-in-the-u-s Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. https://ml.globenewswire.com/media/a20d6f40-90af-422f-ab14-47208fdbad2f/small/amneal-rgb-k-png.png https://www.massachusettshealthcarejournal.com/article/905669769-biovie-announces-abstract-accepted-for-presentation-at-the-2026-american-academy-of-neurology-annual-meeting Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting https://ml.globenewswire.com/media/f437d04b-c089-46eb-bca8-7ef64f68bc9b/small/biovie-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905669779-grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 https://ml.globenewswire.com/media/c71c0a95-caed-4520-87a9-ac7fefef3f07/small/grce-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905670492-er-kim-signs-exclusive-distribution-agreement-with-leo-pharma-a-s-to-commercialize-loqtorzi-toripalimab-for-nasopharyngeal-and-oesophageal-cancers Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers https://ml.globenewswire.com/media/37d25207-4dc0-4c58-b0cc-d589d363d644/small/erkim-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905670506-hinge-bio-announces-first-subject-dosed-in-phase-1-trial-of-hb2198-a-novel-b-cell-depleting-agent-for-treating-autoimmune-disease Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Hinge Bio Announces First Subject Dosed in Phase 1 Trial of HB2198, a Novel B cell Depleting Agent, for Treating Autoimmune Disease https://ml.globenewswire.com/media/62e1a1c6-154c-4dec-bfb4-79d43b015626/small/hinge-logo-color-2021-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905671256-genecentric-to-present-data-on-fragmentomics-based-expressct-liquid-biopsy-technology-at-aacr-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 https://ml.globenewswire.com/media/90d634f2-8dea-4f53-805f-e1e0eaa71133/small/genecentric-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905671300-rivus-pharmaceuticals-announces-first-patients-dosed-in-amplify-phase-2-trial-for-hu6-in-mash Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH https://ml.globenewswire.com/media/b85bbdee-9fda-4cf2-a14f-d2d608f0b949/small/rivus-pharmaceuticals-logo-png.png https://www.massachusettshealthcarejournal.com/article/905671534-carlsmed-inc-to-report-first-quarter-2026-financial-results-on-may-5-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026 https://ml.globenewswire.com/media/ee16eff2-e0d6-40ca-95c5-4dd84bb4cc5f/small/carlsmed-png.png https://www.massachusettshealthcarejournal.com/article/905671584-nanox-announces-collaboration-with-meir-medical-center-to-deploy-nanox-arc-for-orthopedic-imaging-clinical-study Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Nanox Announces Collaboration with Meir Medical Center to Deploy Nanox.ARC for Orthopedic Imaging Clinical Study https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905672627-corbus-pharmaceuticals-announces-last-patient-first-visit-in-canyon-1-study-of-crb-913-for-the-treatment-for-obesity Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905672678-tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts https://ml.globenewswire.com/media/6ddb04fb-e5ac-416b-b90b-b4cbf51dc538/small/blue-logo-stacked-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905672686-genvor-announces-strategic-memorandum-of-understanding-with-canlab-international-to-advance-commercial-peptide-pipeline Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline https://ml.globenewswire.com/media/8533fef9-aa8f-43c5-9088-39ab06147641/small/43464-png.png https://www.massachusettshealthcarejournal.com/article/905672832-real-world-evidence-and-industry-momentum-builds-for-imdx-s-flagship-graftassure-assay Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay https://ml.globenewswire.com/media/418fe8d1-a6a4-4025-84ba-56f14ee83865/small/imdx-logo-png.png https://www.massachusettshealthcarejournal.com/article/905673675-calidi-biotherapeutics-announces-speaker-presentation-at-iovc-conference-in-reykjav-k-iceland-on-april-28th-highlighting-the-redtail-platform-s Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905674131-aclarion-receives-pinnacle-award-for-ai-innovation Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Aclarion Receives Pinnacle Award for AI Innovation https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.massachusettshealthcarejournal.com/article/905674226-r1-announces-revenue-performance-solutions-powered-by-phare-os-to-help-providers-navigate-growing-complexity-and-margin-pressure Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 R1 Announces Revenue Performance Solutions Powered by Phare OS to Help Providers Navigate Growing Complexity and Margin Pressure https://ml.globenewswire.com/media/728189a4-e254-443f-8452-315403fd70f4/small/r1-logo-black-25-947x676-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905674385-prenetics-im8-health-partners-with-vitamin-angels-to-combat-global-malnutrition-commits-to-impacting-400-000-mothers-and-children-in-year-one Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Prenetics’ IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One https://ml.globenewswire.com/media/106dbe1a-a6e1-49d9-97a2-c5609258bdc7/small/pre-logo-2026-png.png https://www.massachusettshealthcarejournal.com/article/905674450-clairity-announces-update-to-nccn-guidelines-to-include-ai-mammogram-based-risk-tool-to-identify-future-breast-cancer-risk-in-women-missed-by Massachusetts Healthcare Journal en PressRelease 2026-04-14T12:00:00+00:00 Clairity Announces Update to NCCN Guidelines to Include AI Mammogram-Based Risk Tool to Identify Future Breast Cancer Risk in Women Missed by Traditional Methods https://ml.globenewswire.com/media/0087b812-cef6-4183-8b7c-093385f3bcb5/small/clairitylogo-fullcolor-vertical-rgb-png.png https://www.massachusettshealthcarejournal.com/article/905671949-avita-medical-announces-positive-interim-results-from-cohealyx-study-demonstrating-accelerated-time-to-skin-grafting Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:45:00+00:00 AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting https://ml.globenewswire.com/media/53ad8139-952a-4470-9ede-2f3bf0521f16/small/avita-png.png https://www.massachusettshealthcarejournal.com/article/905674267-clearmind-medicine-s-cmnd-100-meets-primary-endpoint-in-fda-approved-phase-i-iia-clinical-trial-for-alcohol-use-disorder Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:32:00+00:00 Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905670306-sanara-medtech-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:30:00+00:00 Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/591eb30b-d3e4-428c-9cd6-536215925b01/small/logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905671016-profound-medical-to-participate-in-the-2026-bloom-burton-co-healthcare-investor-conference Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:30:00+00:00 Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/94d9e057-9de3-430c-9a19-b41ff3e06a1e/small/profound-logo-cmyk-copy-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905671585-praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:30:00+00:00 Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905672048-anavex-life-sciences-highlights-new-scientific-findings-on-shared-biology-between-autism-and-alzheimer-s-disease Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:30:00+00:00 Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png https://www.massachusettshealthcarejournal.com/article/905674084-medicenna-to-present-at-the-2026-bloom-burton-co-healthcare-investor-conference Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:30:00+00:00 Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/1644a38b-bed9-4a76-96fa-d57dd028e650/small/medicenna-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905674299-avacta-ceo-christina-coughlin-named-as-one-of-in-vivo-s-2026-rising-leaders Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:26:11+00:00 Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders https://ml.globenewswire.com/media/63584766-21c6-42e8-944c-7103432b045b/small/avacta-logo-full-color-rgb-oct-2024-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905669756-adagene-adds-industry-veteran-peter-lebowitz-to-scientific-and-strategic-advisory-board Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png https://www.massachusettshealthcarejournal.com/article/905669823-trained-therapeutix-discovery-s-chief-scientific-officer-dr-mulder-honored-with-fellowship-at-the-american-institute-for-medical-and-biological Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE) https://ml.globenewswire.com/media/5f6e0329-ec9c-4ab1-9659-d99b938cce16/small/trained-therapeutix-logo-png.png https://www.massachusettshealthcarejournal.com/article/905671051-shopify-to-announce-first-quarter-2026-financial-results-may-5-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 Shopify to Announce First-Quarter 2026 Financial Results May 5, 2026 https://ml.globenewswire.com/media/28cdf29b-fa48-43e3-a710-ea3ab811a26c/small/shopify-logo-black-png.png https://www.massachusettshealthcarejournal.com/article/905671069-axogen-inc-to-report-first-quarter-2026-financial-results-on-april-28-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026 https://ml.globenewswire.com/media/3e4ffe78-2e9a-4972-915e-28c8477c84c1/small/axogen-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905671091-vitalhub-announces-novari-health-referral-central-intake-implementation-in-ontario Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 VitalHub Announces Novari Health Referral Central Intake Implementation in Ontario https://ml.globenewswire.com/media/fae8da93-7d5e-4eb4-9121-d724c8555bce/small/greylogo-png.png https://www.massachusettshealthcarejournal.com/article/905672083-evolveimmune-therapeutics-to-present-update-on-lead-asset-evolve104-and-new-data-for-evolve-t-cell-engager-platform-at-2026-aacr-annual-meeting Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting https://ml.globenewswire.com/media/43892ec0-88ad-4f85-b32e-7d049f9ed422/small/evolveimmune-png.png https://www.massachusettshealthcarejournal.com/article/905673210-ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905673892-ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filspari-sparsentan-in-fsgs Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS https://ml.globenewswire.com/media/1fe91aa2-494e-4b30-89e8-cad771bbaabf/small/new-ligand-logo-png.png https://www.massachusettshealthcarejournal.com/article/905674161-tiziana-life-sciences-announces-late-breaking-poster-accepted-for-presentation-at-the-7th-world-parkinson-congress Massachusetts Healthcare Journal en PressRelease 2026-04-14T11:00:00+00:00 Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress https://ml.globenewswire.com/media/991c340c-a083-4bcb-ad41-e7eea83f6f97/small/tiziana-logo-png.png https://www.massachusettshealthcarejournal.com/article/905658105-genmab-announces-net-sales-of-darzalex-daratumumab-for-first-quarter-of-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-14T10:22:57+00:00 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 https://ml-eu.globenewswire.com/media/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce/small/logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905658895-ataibeckley-to-participate-in-upcoming-needham-healthcare-conferences Massachusetts Healthcare Journal en PressRelease 2026-04-14T10:00:00+00:00 AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences https://ml.globenewswire.com/media/cea08bf4-0562-45ed-af5c-c9376c48a6eb/small/ataibeckley-horizontal-2color-png.png https://www.massachusettshealthcarejournal.com/article/905659602-greenwich-lifesciences-provides-update-on-financing-strategy Massachusetts Healthcare Journal en PressRelease 2026-04-14T10:00:00+00:00 Greenwich LifeSciences Provides Update on Financing Strategy https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905647186-nxera-pharma-s-quviviq-daridorexant-25mg-and-50mg-receives-approval-in-taiwan-for-the-treatment-of-insomnia Massachusetts Healthcare Journal en PressRelease 2026-04-14T08:42:59+00:00 Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://www.massachusettshealthcarejournal.com/article/905636102-mestag-therapeutics-selected-to-present-targeted-ltbr-agonist-mst-0312-in-late-breaking-session-at-aacr-annual-meeting Massachusetts Healthcare Journal en PressRelease 2026-04-14T07:30:00+00:00 Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting https://ml-eu.globenewswire.com/media/d47c1200-a3a8-42b0-b0b9-ffb74568b42c/small/mestag-tx-logo-png.png https://www.massachusettshealthcarejournal.com/article/905636143-asgard-therapeutics-appoints-professor-dr-wolfram-brugger-as-chief-medical-officer-as-it-advances-transformative-personalized-off-the-shelf Massachusetts Healthcare Journal en PressRelease 2026-04-14T07:30:00+00:00 Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development https://ml-eu.globenewswire.com/media/5afbd1fa-9d4b-48d2-8f4f-d262d5a69053/small/asgard-tx-rgb-png.png https://www.massachusettshealthcarejournal.com/article/905614729-panntherapi-annonce-des-avanc-es-majeures-dans-son-d-veloppement-clinique-et-strat-gique Massachusetts Healthcare Journal en PressRelease 2026-04-14T06:00:00+00:00 PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique https://ml-eu.globenewswire.com/media/79af9499-0fbe-4979-88f5-7c607773acb4/small/ https://www.massachusettshealthcarejournal.com/article/905614774-renaissance-pharma-limited-an-essential-pharma-company-secures-fda-fast-track-designation-and-ind-clearance-for-daretabart-hu1418k322a-in Massachusetts Healthcare Journal en PressRelease 2026-04-14T06:00:00+00:00 Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma https://ml-eu.globenewswire.com/media/31276511-f379-4a7a-90b6-af9fc9ac2aa0/small/66795319ca361c8d044a2cc6-essential-pharma-master-logo-png.png https://www.massachusettshealthcarejournal.com/article/905614817-panntherapi-announces-significant-clinical-development-and-strategic-milestones Massachusetts Healthcare Journal en PressRelease 2026-04-14T06:00:00+00:00 PannTheraPi Announces Significant Clinical Development and Strategic Milestones https://ml-eu.globenewswire.com/media/79af9499-0fbe-4979-88f5-7c607773acb4/small/logo-png.png https://www.massachusettshealthcarejournal.com/article/905614845-kuros-biosciences-reports-51-year-over-year-increase-in-sales-in-the-first-three-months-of-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-14T05:00:00+00:00 Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 https://ml-eu.globenewswire.com/media/ad3777c9-af1f-4b09-a899-3b3d6b8e962d/small/kuros-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905593433-rapid-nutrition-strengthens-capital-markets-infrastructure-with-appointment-of-bowsprit-partners Massachusetts Healthcare Journal en PressRelease 2026-04-14T03:00:00+00:00 Rapid Nutrition Strengthens Capital Markets Infrastructure with Appointment of Bowsprit Partners https://ml-eu.globenewswire.com/media/f5152816-94d7-4584-a49f-05ae66a44bf0/small/rapid-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905574910-elite-force-xl-male-enhancement-gummies-claims-evaluated-effective-men-s-formula-for-steel-power-support Massachusetts Healthcare Journal en PressRelease 2026-04-14T01:36:27+00:00 Elite Force XL Male Enhancement Gummies Claims Evaluated: Effective Men's Formula for Steel Power Support https://zingfast.com/wp-content/uploads/2026/04/Elite-Force-XL-Male-Enhancement-Gummies.jpg https://www.massachusettshealthcarejournal.com/article/905574767-vital-step-glp-1-claims-evaluated-trusted-doctor-prescribed-glp-1-weight-loss-medication-with-no-hidden-fees Massachusetts Healthcare Journal en PressRelease 2026-04-14T01:11:21+00:00 Vital Step GLP-1 Claims Evaluated: Trusted Doctor-Prescribed GLP-1 Weight Loss Medication with No Hidden Fees https://zingfast.com/wp-content/uploads/2026/04/Vital-Step-GLP-1.jpg https://www.massachusettshealthcarejournal.com/article/905565700-gloramd-face-lift-serum-claims-evaluated-liquid-anti-aging-wrinkle-serum-solution-for-skin-renewal Massachusetts Healthcare Journal en PressRelease 2026-04-14T00:16:02+00:00 GloraMD Face Lift Serum Claims Evaluated: Liquid Anti-Aging Wrinkle Serum Solution for Skin Renewal https://zingfast.com/wp-content/uploads/2026/04/GloraMD-Face-Lift-Serum.jpg https://www.massachusettshealthcarejournal.com/article/905557661-biomerica-reports-third-quarter-fiscal-2026-financial-results Massachusetts Healthcare Journal en PressRelease 2026-04-13T22:57:27+00:00 Biomerica Reports Third Quarter Fiscal 2026 Financial Results https://ml.globenewswire.com/media/3461b9f0-3e95-484f-96e9-71608fc20239/small/biomerica-png.png https://www.massachusettshealthcarejournal.com/article/905557520-clean-eye-claims-evaluated-the-cleaneye-vision-care-capsules-for-retina-clear-visual-support Massachusetts Healthcare Journal en PressRelease 2026-04-13T22:46:54+00:00 Clean Eye Claims Evaluated: The CleanEye Vision Care Capsules for Retina Clear Visual Support https://zingfast.com/wp-content/uploads/2026/04/Clean-Eye.jpg https://www.massachusettshealthcarejournal.com/article/905549775-ballad-health-s-program-for-assisting-uninsured-patients-earns-national-award-for-its-community-based-approach-to-serving-rural-appalachia Massachusetts Healthcare Journal en PressRelease 2026-04-13T22:06:57+00:00 Ballad Health’s program for assisting uninsured patients earns national award for its community-based approach to serving rural Appalachia https://ml.globenewswire.com/media/MWQ0YWI3MDEtY2Q2Mi00NDk0LTk5MDAtNTEwNTEyYzRjY2Y5LTExMzUxNTItMjAyNi0wNC0xMy1lbg==/tiny/Ballad-Health.png https://www.massachusettshealthcarejournal.com/article/905549588-aim-immunotech-provides-routine-update-on-annual-filings Massachusetts Healthcare Journal en PressRelease 2026-04-13T22:00:00+00:00 AIM ImmunoTech Provides Routine Update on Annual Filings https://ml.globenewswire.com/media/8e85b83b-047f-4f99-9c51-1aa232ffe9bb/small/aimlogo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905542434-xortx-announces-closing-of-acquisition-of-vectus-kidney-anti-fibrotic-asset Massachusetts Healthcare Journal en PressRelease 2026-04-13T21:00:00+00:00 XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset https://ml.globenewswire.com/media/9898c4f8-b373-438a-abfa-709c4372a061/small/xortx-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905542368-spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:46:48+00:00 Spyre Therapeutics Announces Proposed Public Offering of its Common Stock https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905535759-immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-guillemette-and-dr-anthony-dimarco-to-the-board-and-moves-to-a-smaller Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:38:05+00:00 ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors https://ml.globenewswire.com/media/680330c2-368b-4abc-9429-878b0c9fb1a2/small/immucell-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905535401-bioage-labs-to-present-at-25th-annual-needham-virtual-healthcare-conference Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:30:00+00:00 BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/d6df9eb5-87f7-4e2e-b503-8a7d8651428e/small/bioage-dark-logo-white-bg-500x500-png.png https://www.massachusettshealthcarejournal.com/article/905535572-cema-cel-pivotal-trial-interim-data-highlight-strength-of-cellectis-allogeneic-car-t-platform Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:30:00+00:00 Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.massachusettshealthcarejournal.com/article/905535574-les-donn-es-interm-diaires-de-l-essai-pivot-testant-cema-cel-mettent-en-vidence-la-solidit-de-la-plateforme-car-t-allog-nique-de-cellectis Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:30:00+00:00 Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la plateforme CAR-T allogénique de Cellectis https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.massachusettshealthcarejournal.com/article/905535321-sana-biotechnology-and-mayo-clinic-announce-strategic-collaboration-focused-on-improving-care-in-type-1-diabetes-and-accelerating-development-of-sc451 Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:05:00+00:00 Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451 https://ml.globenewswire.com/media/2e5b81be-ddf0-4a60-85f1-3f17c242e8c2/small/sana-biotechnology-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905535567-bridgebio-oncology-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:05:00+00:00 BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/f5f2b913-06aa-4e1d-9368-55ff15fb3bd6/small/bbot-fullcolor-rgb-png.png https://www.massachusettshealthcarejournal.com/article/905535390-celldex-to-present-at-upcoming-investor-conference Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:01:00+00:00 Celldex to Present at Upcoming Investor Conference https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://www.massachusettshealthcarejournal.com/article/905535566-revolution-medicines-inc-announces-proposed-offerings-of-common-stock-and-convertible-senior-notes Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:01:00+00:00 Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.massachusettshealthcarejournal.com/article/905535570-allogene-therapeutics-announces-proposed-public-offering-of-175-million-of-common-stock Massachusetts Healthcare Journal en PressRelease 2026-04-13T20:01:00+00:00 Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://www.massachusettshealthcarejournal.com/article/905522414-celebrating-national-medical-laboratory-week Massachusetts Healthcare Journal en PressRelease 2026-04-13T19:00:00+00:00 Celebrating National Medical Laboratory Week https://ml.globenewswire.com/media/ZWNlYTAwM2UtZDAwNS00MDFjLWJiY2ItZDE4ZTM2YzQyMTM2LTEwOTc1MzMtMjAyNi0wNC0xMy1lbg==/tiny/LifeLabs.png https://www.massachusettshealthcarejournal.com/article/905516650-seer-confirms-receipt-of-unsolicited-proposal-and-director-candidate-nominations-from-radoff-jec-group Massachusetts Healthcare Journal en PressRelease 2026-04-13T17:55:00+00:00 Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group https://ml.globenewswire.com/media/a5aaadad-13a1-4dbd-8ba2-d57cbbc610fb/small/seer-brandmark-rgb-full-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905516710-vital-hemp-gummies-launch-hemp-gummies-australia-nz-or-canada-relieves-anxiety-effective-reduces-pain-relax-stress-with-vital-hemp-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-13T17:39:33+00:00 Vital Hemp Gummies | Launch" Hemp Gummies Australia, NZ Or Canada Relieves Anxiety Effective Reduces Pain Relax Stress With Vital Hemp 2026 https://ml-eu.globenewswire.com/Resource/Download/3dd4c2ca-9658-477e-9266-ac54964587d8/image1.png https://www.massachusettshealthcarejournal.com/article/905402725-sunway-medical-centre-penang-recognized-as-emerging-tertiary-medical-hub-malaysia-by-global-brand-frontier-awards-2025 Massachusetts Healthcare Journal en PressRelease 2026-04-13T05:38:09+00:00 Sunway Medical Centre Penang Recognized as Emerging Tertiary Medical Hub – Malaysia by Global Brand Frontier Awards 2025 https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24830973-sunway-medical-main-3750x1969.jpeg https://www.massachusettshealthcarejournal.com/article/905511446-dermatology-devices-market-to-reach-25-6-billion-by-2030-driven-by-rising-skin-cancer-incidence-and-aesthetic-demand Massachusetts Healthcare Journal en PressRelease 2026-04-13T17:21:11+00:00 Dermatology Devices Market to Reach $25.6 Billion by 2030, Driven by Rising Skin Cancer Incidence and Aesthetic Demand https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.massachusettshealthcarejournal.com/article/905511391-ask4sam-nyc-medical-malpractice-attorneys-silberstein-miklos-p-c-expands-focus-on-representing-patients-across-manhattan-brooklyn-and-queens Massachusetts Healthcare Journal en PressRelease 2026-04-13T17:05:00+00:00 ASK4SAM NYC Medical Malpractice Attorneys Silberstein & Miklos, P.C. Expands Focus on Representing Patients Across Manhattan, Brooklyn and Queens https://pressranger.s3.us-west-1.amazonaws.com/3228765/8.png https://www.massachusettshealthcarejournal.com/article/905506130-centre-for-neuro-skills-named-to-newsweek-s-america-s-greatest-midsize-workplaces-in-health-care-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-13T16:17:00+00:00 Centre for Neuro Skills Named to Newsweek’s America’s Greatest Midsize Workplaces in Health Care 2026 https://ml.globenewswire.com/media/3157a281-770d-4ef2-ade7-353df4ceca6b/medium/image2.png https://www.massachusettshealthcarejournal.com/article/905506215-sienna-for-seniors-foundation-1-million-gift-advances-healthy-aging-research-at-ontario-tech-university Massachusetts Healthcare Journal en PressRelease 2026-04-13T16:13:38+00:00 Sienna for Seniors Foundation $1 Million Gift Advances Healthy Aging Research at Ontario Tech University https://ml.globenewswire.com/media/9765702b-cb47-4b36-8255-d86b22ef3df3/medium/ontario-tech-university-and-sienna-senior-living-celebrate-t.jpg https://www.massachusettshealthcarejournal.com/article/905506159-radical-catheter-technologies-announces-u-s-fda-510-k-clearance-for-its-6f-neurovascular-catheter-broadening-access-across-a-wide-range-of Massachusetts Healthcare Journal en PressRelease 2026-04-13T16:05:00+00:00 Radical™ Catheter Technologies Announces U.S. FDA 510(k) Clearance for its 6F Neurovascular Catheter -- Broadening Access Across a Wide Range of Applications https://ml.globenewswire.com/media/5177f2ec-c584-4237-9659-cc7c70377b47/small/radical-catheter-stacked-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905501361-american-kidney-fund-announces-2026-class-of-corporate-members-supporting-work-to-fight-kidney-disease Massachusetts Healthcare Journal en PressRelease 2026-04-13T15:37:08+00:00 American Kidney Fund Announces 2026 Class of Corporate Members Supporting Work to Fight Kidney Disease https://ml.globenewswire.com/media/MDkzZjJmMDYtN2I0OC00MTYwLWFlNTItZTBlNDJlMDBmNDk0LTExMDkwNTItMjAyNi0wNC0xMy1lbg==/tiny/American-Kidney-Fund.png https://www.massachusettshealthcarejournal.com/article/905483211-biomx-accelerates-defense-technology-buildout-with-dfsl-acquisition Massachusetts Healthcare Journal en PressRelease 2026-04-13T13:20:00+00:00 BiomX Accelerates Defense Technology Buildout with DFSL Acquisition https://ml.globenewswire.com/media/OGZiY2U5N2EtNDEzNS00MjcyLWJiZjUtODViOTA2ZTkxZjdhLTEzMjE4NzEtMjAyNi0wNC0xMy1lbg==/tiny/BiomX.png https://www.massachusettshealthcarejournal.com/article/905482689-polypid-to-present-new-phase-3-shield-ii-data-demonstrating-d-plex-sustained-local-release-at-escmid-global-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-13T13:15:00+00:00 PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 https://ml.globenewswire.com/media/6016c990-606d-49e6-a7a8-4d88bace509a/medium/figure-1.png https://www.massachusettshealthcarejournal.com/article/905483265-safespace-global-corporation-announces-operational-expansion-to-support-commercial-deployment-of-its-ai-safety-platform-and-growing-revenue-activities Massachusetts Healthcare Journal en PressRelease 2026-04-13T13:15:00+00:00 SafeSpace Global Corporation Announces Operational Expansion to Support Commercial Deployment of its AI-safety platform and Growing Revenue Activities https://ml.globenewswire.com/media/e95639ca-a47d-4c90-a44e-cf8a03b6a6d2/small/logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905482794-switchback-medical-signs-lease-for-18-000-square-foot-facility-in-costa-rica-s-coyol-free-trade-zone Massachusetts Healthcare Journal en PressRelease 2026-04-13T13:00:00+00:00 Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Rica’s Coyol Free Trade Zone https://ml.globenewswire.com/media/de124664-5d20-4955-8016-3dc40767830c/small/switchback-png.png https://www.massachusettshealthcarejournal.com/article/905482824-switchback-medical-firma-contrato-de-arrendamiento-para-una-instalaci-n-de-18-000-pies-cuadrados-en-la-zona-franca-coyol-de-costa-rica Massachusetts Healthcare Journal en PressRelease 2026-04-13T13:00:00+00:00 Switchback Medical firma contrato de arrendamiento para una instalación de 18,000 pies cuadrados en la Zona Franca Coyol de Costa Rica https://ml.globenewswire.com/media/de124664-5d20-4955-8016-3dc40767830c/small/switchback-png.png https://www.massachusettshealthcarejournal.com/article/905482882-neomorph-announces-closing-of-100-million-series-b-financing Massachusetts Healthcare Journal en PressRelease 2026-04-13T13:00:00+00:00 Neomorph Announces Closing of $100 Million Series B Financing https://ml.globenewswire.com/media/d00180c1-5def-41b6-95c7-018ca5e07565/small/neomorph-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905482931-senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-session-at-aacr-annual-meeting-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-13T13:00:00+00:00 Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 https://ml.globenewswire.com/media/19732ef2-d354-4281-9dc5-6000f190dd83/small/sentibiologo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905478607-free-oral-cancer-screenings-in-honor-of-oral-head-and-neck-cancer-awareness-month Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:45:00+00:00 Free Oral Cancer Screenings in Honor of Oral, Head and Neck Cancer Awareness Month https://ml.globenewswire.com/media/9472c27c-8b6d-4c87-95fd-31f1f0140263/small/usosm-logo-png.png https://www.massachusettshealthcarejournal.com/article/905478665-xealth-to-facilitate-critical-discussion-among-health-system-executives-on-how-to-maximize-digital-health-value-at-becker-s-annual-meeting Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:33:00+00:00 Xealth to Facilitate Critical Discussion Among Health System Executives on How to Maximize Digital Health Value at Becker’s Annual Meeting https://ml.globenewswire.com/media/33a9b40b-a04e-464b-b15f-f7180c2168ce/small/picture1-png.png https://www.massachusettshealthcarejournal.com/article/905478602-optum-united-healthcare-united-behavioral-health-expands-neurostar-tms-coverage-to-include-psychiatric-mental-health-nurse-practitioners Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:32:00+00:00 Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.massachusettshealthcarejournal.com/article/905478464-alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:30:00+00:00 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer https://ml.globenewswire.com/media/0a1b4459-3df3-4c9f-ba29-ace8d7ad1b9a/small/alx-01-stacked-white-png.png https://www.massachusettshealthcarejournal.com/article/905478584-oragenics-doses-first-patient-in-phase-iia-clinical-trial-of-onp-002-for-mild-traumatic-brain-injury Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:30:00+00:00 Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury https://ml.globenewswire.com/media/8b2c9d06-f009-4a6e-a465-8a1fe9640993/small/logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905478638-microbot-medical-commences-full-market-release-fmr-of-the-liberty-endovascular-robotic-system-in-the-u-s-at-the-society-of-interventional Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:30:00+00:00 Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905478648-heartflow-files-patent-infringement-lawsuit-against-cleerly Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:30:00+00:00 Heartflow Files Patent Infringement Lawsuit Against Cleerly https://ml.globenewswire.com/media/c6be111e-2f8e-4ac8-8fa8-310dbcbd6e15/small/25-1113-cmyk-hf-logo-positive-png.png https://www.massachusettshealthcarejournal.com/article/905478660-inspira-begins-ame-technology-implementation-process-with-one-of-the-world-s-10-largest-u-s-based-companies Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:16:00+00:00 Inspira Begins AME Technology Implementation Process with One of the World's 10 Largest U.S. Based Companies https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://www.massachusettshealthcarejournal.com/article/905478477-chemed-corporation-announces-a-five-year-450-million-amended-and-restated-credit-agreement Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:15:00+00:00 Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905474851-nanox-signs-distribution-agreement-with-digital-x-ray-imaging-to-expand-nanox-arc-adoption-in-arkansas Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:10:00+00:00 Nanox Signs Distribution Agreement with Digital X-Ray Imaging to Expand Nanox.ARC Adoption in Arkansas https://ml-eu.globenewswire.com/media/7a1764f8-84e3-4b28-ae23-9add5d57c378/small/nanox-logo-4-png.png https://www.massachusettshealthcarejournal.com/article/905474794-veld-pharmaceuticals-gmbh-announces-collaboration-with-chiesi-farmaceutici-s-p-a-to-expand-access-to-rare-disease-therapies-across-africa Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa https://ml-eu.globenewswire.com/media/047cc83e-f777-4658-9d34-e499423ec123/small/logo-veld-png.png https://www.massachusettshealthcarejournal.com/article/905474801-impact-biotech-presents-preliminary-data-from-phase-1-study-of-padeliporfin-vtp-in-la-pdac-at-sir-2026-and-provides-strategic-business-update Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update https://ml-eu.globenewswire.com/media/68762066-1fff-4065-af45-d18da25273cd/small/impact-biotech-logo-final-resized-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905474927-geron-announces-appointment-of-timothy-williams-as-executive-vice-president-chief-legal-officer-and-corporate-secretary Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905474962-pacira-presents-real-world-data-on-exparel-showing-lower-total-healthcare-costs-in-outpatient-total-hip-and-knee-arthroplasty-procedures Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures https://ml.globenewswire.com/media/3e502c92-e576-46b6-b602-a177ab0f5044/small/pacira-biosciences-tm-logo-rgb-v2025-300dpi-adj-png.png https://www.massachusettshealthcarejournal.com/article/905474978-brainsway-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/ea01c8f7-39be-46d2-a8e0-bc05994f170e/small/brainsway-2021-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905474988-septerna-announces-initiation-of-phase-1-clinical-trial-of-sep-479-an-oral-small-molecule-pth1r-agonist-for-the-treatment-of-hypoparathyroidism Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism https://ml.globenewswire.com/media/8c635733-2794-456f-9bc4-3b53908acba9/small/septernalogo-black-10x-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905475004-favorable-results-of-ovarian-cancer-study-presented-at-annual-society-of-gynecological-care-conference Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905475007-stryker-signs-definitive-agreement-to-acquire-amplitude-vascular-systems-to-add-next-generation-ivl-technology-to-peripheral-vascular-portfolio Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio https://ml.globenewswire.com/media/c24fe8bd-9db6-4f42-8a52-06a4e1b673b5/small/stryker-logo2015-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905475009-praxis-to-showcase-essential3-the-first-positive-phase-3-program-in-essential-tremor-at-aan-2026 Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905475038-cvrx-reports-preliminary-first-quarter-2026-financial-results Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 CVRx Reports Preliminary First Quarter 2026 Financial Results https://ml.globenewswire.com/media/04c4feba-7841-4ac8-8ca5-6c03be383a0e/small/cvrx-outsmart-the-heart-logo-rgb-blue-png.png https://www.massachusettshealthcarejournal.com/article/905475045-daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-pivotal-phase-3-rasolute-302-clinical-trial-in-patients-with-metastatic-pancreatic Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.massachusettshealthcarejournal.com/article/905475055-eupraxia-pharmaceuticals-to-present-at-upcoming-investor-conferences Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/0b2bbe4b-1cf9-402e-8ea6-22c0043f310a/small/eupraxia-color-med-res-01-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905475064-akebia-therapeutics-announces-first-participants-dosed-in-phase-1-clinical-trial-of-akb-9090 Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.massachusettshealthcarejournal.com/article/905475065-catheter-precision-announces-accepted-publication-in-leading-european-medical-journal Massachusetts Healthcare Journal en PressRelease 2026-04-13T12:00:00+00:00 Catheter Precision Announces Accepted Publication in Leading European Medical Journal https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905474987-nervgen-pharma-to-participate-in-the-h-c-wainwright-hcw-home-series-and-the-2026-bloom-burton-co-healthcare-investor-conference Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:45:00+00:00 NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.massachusettshealthcarejournal.com/article/905475034-with-brain-scan-volume-momentum-accelerating-firefly-makes-history-by-building-the-world-s-first-known-200-000-standardized-eeg-erp-depository Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:45:00+00:00 With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository https://ml.globenewswire.com/media/cd317e6a-730f-4537-a096-9b724abb964e/small/firefly-png.png https://www.massachusettshealthcarejournal.com/article/905470717-allogene-therapeutics-reports-interim-futility-analysis-from-pivotal-alpha3-trial-showing-58-3-mrd-clearance-with-cemacabtagene-ansegedleucel Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:30:00+00:00 Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL https://ml.globenewswire.com/media/87e8712c-0741-409f-9942-c91b31e7c5e1/small/allogene-png.png https://www.massachusettshealthcarejournal.com/article/905470753-vireo-growth-announces-california-retail-joint-venture-with-glass-house-brands Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:30:00+00:00 Vireo Growth Announces California Retail Joint Venture with Glass House Brands https://ml.globenewswire.com/media/d01c0dca-8260-48c8-8ead-e09111cf57b5/small/vireo-horizontalllogolockup-01-png.png https://www.massachusettshealthcarejournal.com/article/905470768-newly-published-u-s-expert-consensus-aligns-with-mediwound-s-strategy-for-chronic-wound-debridement Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:30:00+00:00 Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905470778-northstrive-biosciences-announces-u-s-arrival-of-el-32-working-cell-bank-and-initiation-of-manufacturing-optimization-for-dual-myostatin-assets Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:30:00+00:00 NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences https://ml.globenewswire.com/media/b1dabc1a-ea7b-49d8-a9cd-406fd48dd65b/small/logo-color-1-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905470800-palvella-therapeutics-appoints-john-d-doux-m-d-m-b-a-dermatologist-and-recognized-leader-in-rare-skin-diseases-to-board-of-directors Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:30:00+00:00 Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905470793-gelatide-drops-investigated-2026-report-what-consumers-should-verify-before-buying Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:23:50+00:00 Gelatide Drops Investigated (2026 Report) What Consumers Should Verify Before Buying https://ml.globenewswire.com/Resource/Download/984a2986-fdd3-4fe6-80f2-312f9d1cbc94/image2.png https://www.massachusettshealthcarejournal.com/article/905467090-from-milestone-to-momentum-kraig-biocraft-leadership-travels-to-south-east-asia-following-record-setting-1-3-metric-ton-recombinant-spider-silk Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:05:00+00:00 From Milestone to Momentum: Kraig Biocraft Leadership Travels to South East Asia Following Record-Setting 1.3 Metric Ton Recombinant Spider Silk Cocoon Production Cycle https://ml.globenewswire.com/media/3cf5ab91-0822-460b-bb13-17447941c84a/small/kblb-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905466754-oxb-launches-fast-track-offering-for-aav-and-lentiviral-vector-platforms-accelerating-viral-vector-development-and-manufacture Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:00:00+00:00 OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture https://ml-eu.globenewswire.com/media/3e905c0a-b28c-4981-ac57-745647779ad9/small/oxb-new-logo-png.png https://www.massachusettshealthcarejournal.com/article/905466795-eclipse-life-sciences-completes-enrollment-in-phase-2-study-evaluating-ec-104-for-diabetic-macular-edema-dme Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:00:00+00:00 Eclipse Life Sciences Completes Enrollment in Phase 2 Study Evaluating EC-104 for Diabetic Macular Edema (DME) https://ml.globenewswire.com/media/3ed9dd28-ed00-4f7d-b5b9-1180c2c99262/small/eclipse-logo-png.png https://www.massachusettshealthcarejournal.com/article/905466931-soleo-health-opens-new-ambulatory-infusion-center-in-louisville-kentucky Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:00:00+00:00 Soleo Health Opens New Ambulatory Infusion Center in Louisville, Kentucky https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://www.massachusettshealthcarejournal.com/article/905466947-nrx-pharmaceuticals-nasdaq-nrxp-announces-appointment-of-glenn-tyson-as-the-company-s-first-chief-commercial-officer Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.massachusettshealthcarejournal.com/article/905466972-kymera-therapeutics-announces-u-s-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-moderate-to Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:00:00+00:00 Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.massachusettshealthcarejournal.com/article/905466973-spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:00:00+00:00 Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905466986-ocular-therapeutix-announces-additional-positive-week-52-data-from-landmark-sol-1-phase-3-trial-of-axpaxli-in-wet-amd Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:00:00+00:00 Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905467081-imagenebio-announces-30-million-private-placement Massachusetts Healthcare Journal en PressRelease 2026-04-13T11:00:00+00:00 ImageneBio Announces $30 Million Private Placement https://ml.globenewswire.com/media/ccccc30d-a51c-48d7-9aec-6b542240c611/small/imagene-logo-green-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905466794-ani-pharmaceuticals-announces-the-launch-of-carbamazepine-extended-release-capsules Massachusetts Healthcare Journal en PressRelease 2026-04-13T10:50:00+00:00 ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://www.massachusettshealthcarejournal.com/article/905467025-leanzene-gummies-examined-2026-consumer-focused-breakdown-of-ingredients-claims-label-transparency Massachusetts Healthcare Journal en PressRelease 2026-04-13T10:47:40+00:00 Leanzene Gummies Examined: 2026 Consumer-Focused Breakdown of Ingredients, Claims & Label Transparency https://ml.globenewswire.com/Resource/Download/e7b8402e-d943-467a-8865-1fec7f5629cc/image2.png https://www.massachusettshealthcarejournal.com/article/905463063-regeneron-and-telix-announce-strategic-radiopharma-collaboration Massachusetts Healthcare Journal en PressRelease 2026-04-13T10:30:00+00:00 Regeneron and Telix Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905463143-telix-and-regeneron-announce-strategic-radiopharma-collaboration Massachusetts Healthcare Journal en PressRelease 2026-04-13T10:30:00+00:00 Telix and Regeneron Announce Strategic Radiopharma Collaboration https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.massachusettshealthcarejournal.com/article/905459654-prosomnus-receives-fda-class-ii-clearance-for-rpmo2-osa-device Massachusetts Healthcare Journal en PressRelease 2026-04-13T10:00:00+00:00 ProSomnus® Receives FDA Class II Clearance for RPMO2 OSA Device https://ml.globenewswire.com/media/333d9b0e-92b8-4e8b-ab32-6689f4113578/medium/prosomnus-rpmo2-osa-device-system.jpg https://www.massachusettshealthcarejournal.com/article/905451931-smart-minimalism-supreme-efficiency-cuktech-15-charging-station-makes-its-debut-in-malaysia Massachusetts Healthcare Journal en PressRelease 2026-04-13T08:40:54+00:00 Smart Minimalism, Supreme Efficiency: CUKTECH 15 Charging Station Makes Its Debut in Malaysia https://ml.globenewswire.com/media/3bf1f045-1f83-4d75-a8c5-1e9f3623347a/medium/image-1.png https://www.massachusettshealthcarejournal.com/article/905452017-berikut-adalah-terjemahan-siaran-akhbar-tersebut-ke-dalam-bahasa-melayu-minimalisme-pintar-kecekapan-ulung-stesen-pengecasan-cuktech-15-membuat Massachusetts Healthcare Journal en PressRelease 2026-04-13T08:40:54+00:00 Berikut adalah terjemahan siaran akhbar tersebut ke dalam Bahasa Melayu: Minimalisme Pintar, Kecekapan Ulung: Stesen Pengecasan CUKTECH 15 Membuat Kemunculan Sulung di Malaysia https://ml.globenewswire.com/media/3bf1f045-1f83-4d75-a8c5-1e9f3623347a/medium/image-1.png https://www.massachusettshealthcarejournal.com/article/905445010-epitopea-strengthens-scientific-advisory-board-with-appointment-of-leading-authority-in-cancer-lisa-butterfield Massachusetts Healthcare Journal en PressRelease 2026-04-13T08:00:00+00:00 Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905445013-epitopea-renforce-son-comit-consultatif-scientifique-avec-la-nomination-de-lisa-butterfield-figure-de-renom-dans-le-domaine-du-cancer Massachusetts Healthcare Journal en PressRelease 2026-04-13T08:00:00+00:00 Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer https://ml.globenewswire.com/media/e42e44d9-eec5-4ff3-a9ee-fab395efd2a8/small/epitopea-instagram-post-2-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905445007-boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows Massachusetts Healthcare Journal en PressRelease 2026-04-13T07:51:00+00:00 Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://www.massachusettshealthcarejournal.com/article/905445021-rising-uk-dental-costs-and-nhs-access-crisis-drive-record-demand-for-treatment-in-t-rkiye-dentspa-leads-the-response Massachusetts Healthcare Journal en PressRelease 2026-04-13T07:30:00+00:00 Rising UK Dental Costs and NHS Access Crisis Drive Record Demand for Treatment in Türkiye — DentSpa Leads the Response https://ml-eu.globenewswire.com/media/53fb3ee2-7271-4c5f-b8b5-f4e6db89cc89/small/dentspa-logo-blue-png.png https://www.massachusettshealthcarejournal.com/article/905432311-transgene-completes-patient-randomization-in-phase-2-part-of-clinical-trial-evaluating-tg4050-in-the-adjuvant-treatment-of-head-and-neck-cancer Massachusetts Healthcare Journal en PressRelease 2026-04-13T06:00:00+00:00 Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer https://ml-eu.globenewswire.com/media/a1e966ec-4255-431c-b28a-c40c9e1f8733/small/transgene-logo-rvb2026-png.png https://www.massachusettshealthcarejournal.com/article/905432314-transgene-annonce-la-fin-de-la-randomisation-des-patients-de-la-partie-phase-2-de-l-essai-clinique-valuant-tg4050-dans-le-traitement-adjuvant-des Massachusetts Healthcare Journal en PressRelease 2026-04-13T06:00:00+00:00 Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou https://ml-eu.globenewswire.com/media/2a0cee23-0b14-48ff-8db2-e5e966dd7bb5/small/transgene-logo-rvb2026-png.png https://www.massachusettshealthcarejournal.com/article/905432318-synox-therapeutics-announces-positive-topline-results-from-the-phase-3-tangent-study-supporting-emactuzumab-as-a-differentiated-next-generation Massachusetts Healthcare Journal en PressRelease 2026-04-13T06:00:00+00:00 SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT) https://ml.globenewswire.com/media/35d87dbe-62e3-4299-9eba-3ccdbea5d85e/small/synox-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905424235-press-release-sanofi-and-regeneron-s-dupixent-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous Massachusetts Healthcare Journal en PressRelease 2026-04-13T05:00:00+00:00 Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905424236-communiqu-de-presse-dupixent-de-sanofi-et-regeneron-approuv-dans-l-ue-comme-premier-m-dicament-cibl-contre-l-urticaire-chronique-spontan-e-chez Massachusetts Healthcare Journal en PressRelease 2026-04-13T05:00:00+00:00 Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905424246-data-published-in-nature-communications-highlights-unique-mechanism-of-action-of-alpibectir-in-combination-with-ethionamide-alpe Massachusetts Healthcare Journal en PressRelease 2026-04-13T05:00:00+00:00 Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE) https://ml.globenewswire.com/media/37dee549-5eb0-418f-a16c-11d8422babfb/small/logo-bioversys-color-rgb-neu-for-prs-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905424249-dupixent-dupilumab-approved-in-the-eu-as-the-first-targeted-medicine-to-treat-young-children-with-chronic-spontaneous-urticaria-csu Massachusetts Healthcare Journal en PressRelease 2026-04-13T05:00:00+00:00 Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.massachusettshealthcarejournal.com/article/905385512-nxera-pharma-s-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia Massachusetts Healthcare Journal en PressRelease 2026-04-12T23:30:00+00:00 Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://www.massachusettshealthcarejournal.com/article/905363129-scrap-the-ban-keep-the-controls-caphra-s-message-to-bangladesh Massachusetts Healthcare Journal en PressRelease 2026-04-12T20:56:25+00:00 Scrap the Ban, Keep the Controls: CAPHRA's Message to Bangladesh https://ml.globenewswire.com/media/6dc95f2d-65fb-409f-aed4-9ebe55554004/small/picture1-png.png